Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip

robot
Abstract generation in progress

Hims & Hers Health stock surged after a report indicated Novo Nordisk plans to sell weight-loss drugs through its platform, despite a recent legal dispute. Meanwhile, Pfizer and Agilent Technologies saw their shares decline due to clinical trial results and an acquisition announcement, respectively. The broader U.S. stock futures also fell amid escalating Middle East conflict driving up energy prices.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin